Watch GCTK. Know when insiders buy.
One email the day a filing lands. Free.
GCTK
Glucotrack, Inc.
2.27
−0.18 −7.35%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $24MP/E 0.2DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$15.9MNET CASH —52W 2.27 – 128.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.4M | −$3.8M | — | 0.76 | −$3.6M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$4.2M | −$4.3M | — | 2.65 | −$4M | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.5M | −$3.6M | — | 1.13 | −$3.9M | $20K | −$4M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$4.3M | −$4.2M | — | 4.64 | −$4.6M | $67K | −$4.7M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$4.8M | −$4.8M | — | 9.62 | −$3.7M | $0 | −$3.7M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3.5M | −$6.8M | — | 40.14 | −$2.9M | $9K | −$2.9M | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.9M | −$10.1M | — | 1238.00 | −$3.5M | $0 | −$3.5M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$3.3M | −$5.1M | — | 1092.00 | −$4.1M | $33K | −$4.2M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$4.5M | −$4.5M | — | 984.00 | −$1.9M | $12K | −$1.9M | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3M | −$2.9M | — | -11.73 | −$2.9M | $59K | −$3M | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.4M | −$2.4M | — | 35.56 | −$2.4M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.2M | −$2.2M | — | -0.49 | −$1.9M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$16.1M | −$19.4M | — | 31.22 | −$15.2M | $96K | −$15.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$14.5M | −$22.6M | — | 4106.00 | −$12.5M | $104K | −$12.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$7.1M | −$7.1M | — | 34.18 | −$6.6M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$4.4M | −$4.4M | — | 0.29 | −$3.7M | $1K | −$3.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$4M | −$4.1M | — | 0.26 | −$3.8M | $5K | −$3.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$3.1M | −$2.7M | — | 0.19 | −$3.5M | $53K | −$3.6M | — | — |
Every number comes from Glucotrack, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.